News · 26 weeks86-77%
2025-12-142026-06-07
Mix5590d
- Insider18(33%)
- SEC Filings17(31%)
- Other13(24%)
- Analyst5(9%)
- Earnings2(4%)
Latest news
25 items- SECSEC Form S-3 filed by Opus Genetics Inc.S-3 - Opus Genetics, Inc. (0001228627) (Filer)
- ANALYSTGuggenheim initiated coverage on Opus Genetics with a new price targetGuggenheim initiated coverage of Opus Genetics with a rating of Buy and set a new price target of $16.00
- PROpus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease ExpertsRESEARCH TRIANGLE PARK, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced the guest speakers for its virtual Research & Development (R&D) Science Forum to be held on Tuesday, June 16, 2026, from 10:00 am – 12:00 pm ET. The R&D Science Forum will feature management and key opinion leaders (KOLs) highlighting Opus Genetics' multi-asset gene therapy pipeline, which is designed to address the underlying genetic causes of severe IRDs. The Forum will include deta
- PROpus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)RESEARCH TRIANGLE PARK, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) (the "Company"), today announced that the Compensation Committee of its Board of Directors approved equity awards under the Company's 2021 Inducement Plan, as amended, as a material inducement to employment to ten non-executive employees who were not previously employees or directors of the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted in the form of options to
- PROpus Genetics to Present at the 2026 Jefferies Global Healthcare ConferenceRESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced today that management will present at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 8:45 a.m. ET. A link to the live and archived webcast may be accessed on Opus Genetics' website under the Investors section: Events. About Opus Genetics Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindne
- ANALYSTLeerink Partners initiated coverage on Opus Genetics with a new price targetLeerink Partners initiated coverage of Opus Genetics with a rating of Outperform and set a new price target of $10.00
- INSIDERDirector Foundation Fighting Blindness Retinal Degeneration Fund sold $7,395,000 worth of shares (1,700,000 units at $4.35) (SEC Form 4)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Opus Genetics Inc.SCHEDULE 13G/A - Opus Genetics, Inc. (0001228627) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Opus Genetics Inc.SCHEDULE 13G/A - Opus Genetics, Inc. (0001228627) (Subject)
- SECSEC Form S-8 filed by Opus Genetics Inc.S-8 - Opus Genetics, Inc. (0001228627) (Filer)
- PROpus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare ConferenceRESEARCH TRIANGLE PARK, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced today that management will present at the RBC Capital Markets 2026 Global Healthcare Conference on Tuesday, May 19, 2026 at 11:00 a.m. ET. A link to the live and archived webcast may be accessed on Opus Genetics' website under the Investors section: Events. About Opus Genetics Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and preven
- SECSEC Form 10-Q filed by Opus Genetics Inc.10-Q - Opus Genetics, Inc. (0001228627) (Filer)
- SECOpus Genetics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Opus Genetics, Inc. (0001228627) (Filer)
- PROpus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate UpdateOpus Genetics Virtual R&D Science Forum Scheduled for Tuesday, June 16, 2026, at 10:00 am ET Upcoming Data Readout for Cohort 1 of OPGx-BEST1 Gene Therapy Study Expected in September 2026 LCA5 Accepted to FDA's Rare Disease Evidence Principles (RDEP) Program and Enrolling Pivotal Trial RDH12, MERTK and RHO Programs Expected to Advance to Clinical Testing in the Next 12 Months Cash Runway into 2029 Expected to Support Multiple Clinical Inflection Points, Potential Product Approvals and Opportunities for Priority Review Vouchers RESEARCH TRIANGLE PARK, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) (the "Company" or "Opus Genetics"), a clinical-stage biopharmac
- PROpus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal DiseasesSix-Month Clinical Data Demonstrate Restoration of Cone-Mediated Vision in Pediatric LCA5 Patients, with Sensitivity Improvements Reaching Normal Ranges Early BEST1 Data Show Visual Acuity Gains and Improved Retinal Structure, Supporting Expansion into a Large IRD Population Preclinical RHO Programs Demonstrate Durable Retinal Preservation and Support Clinical Translation Mutation-Independent AAV Approach Highlights Potential to Address Genetically Diverse Retinal Diseases with a Single Therapy Advancements In Potency Assays and Manufacturing Reinforce Scalability and Regulatory Readiness RESEARCH TRIANGLE PARK, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) (
- PROpus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy StudyTarget Enrollment Achieved with the Inclusion of Participants with Both Dominant and Recessive Forms of BEST Disease Baseline Demographics Presented at ARVO Annual Meeting with Summary Audio and Slide Presentation Available on Opus Website Three-Month Topline Results from Cohort 1 Expected in September 2026 RESEARCH TRIANGLE PARK, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced the completion of enrollment in Cohort 1 of its ongoing Phase 1/2 study of O
- PROpus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) ProgramRESEARCH TRIANGLE PARK, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that its investigational LCA5 gene therapy program, OPGx-LCA5, has been accepted into the U.S. Food and Drug Administration's (FDA) Rare Disease Evidence Principles (RDEP) program. OPGx-LCA5 is a potential gene therapy for Leber congenital amaurosis type 5 (LCA5), a rare inherited retinal disease caused by mutations in the LCA5 gene. The condition leads to early-onset, progressive visi
- ANALYSTCitizens initiated coverage on Opus Genetics with a new price targetCitizens initiated coverage of Opus Genetics with a rating of Mkt Perform and set a new price target of $12.00
- INSIDERChief Operating Officer Schachle Joseph K sold $24,519 worth of shares (4,697 units at $5.22), decreasing direct ownership by 2% to 296,084 units (SEC Form 4) (withholding tax)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- INSIDERPresident Yerxa Benjamin R sold $39,121 worth of shares (7,470 units at $5.24), decreasing direct ownership by 1% to 711,535 units (SEC Form 4) to satisfy withholding obligation4 - Opus Genetics, Inc. (0001228627) (Issuer)
- INSIDERHead of Fin. Quality Assurance Zaremba Rabourn Amy sold $8,540 worth of shares (1,641 units at $5.20), decreasing direct ownership by 0.86% to 188,671 units (SEC Form 4) (for withholding tax)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- INSIDERChief Executive Officer Magrath George sold $49,647 worth of shares (9,511 units at $5.22), decreasing direct ownership by 0.54% to 1,741,344 units (SEC Form 4) (withholding obligation)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- INSIDERChief Scientific & Dev. Ofc. Jayagopal Ashwath sold $39,156 worth of shares (7,542 units at $5.19), decreasing direct ownership by 1% to 509,233 units (SEC Form 4) to cover taxes4 - Opus Genetics, Inc. (0001228627) (Issuer)
- INSIDERChief Financial Officer Gagnon Robert E. sold $40,658 worth of shares (7,842 units at $5.18), decreasing direct ownership by 1% to 592,158 units (SEC Form 4) (withholding obligation)4 - Opus Genetics, Inc. (0001228627) (Issuer)
- PROpus Genetics to Participate in Leading Medical Conferences in May 2026RESEARCH TRIANGLE PARK, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Opus Genetics (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that members of its leadership team will participate in several leading ophthalmology and industry conferences. "We look forward to sharing progress across our programs at ARVO and other leading meetings this May, including encouraging findings from our LCA5 and BEST1 gene therapy programs," said Dr. George Magrath, Chief Executive Officer, Opus Genetics. "At ARVO, we will present previous
IRD FAQ
5 questionsWhere does IRD stock trade?
Opus Genetics Inc. (IRD) is listed on NASDAQ.What sector and industry is IRD in?
Opus Genetics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about IRD?
Opus Genetics Inc. has had 8 recent analyst actions on file. The most recent action was from Guggenheim: Buy with a $1600.00 price target on 2026-06-04. Recent price targets range from $700.00 to $1600.00.What companies are similar to IRD?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare IRD side-by-side with any of them on Quantisnow.How can I track IRD on Quantisnow?
Quantisnow aggregates Opus Genetics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IRD to receive live email and push alerts on every new disclosure.